Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Authors: Maynard, Ashley, McCoach, Caroline E., Rotow, Julia K., Harris, Lincoln, Haderk, Franziska, Kerr, D. Lucas, Yu, Elizabeth A., Schenk, Erin L., Tan, Weilun, Zee, Alexander, Tan, Michelle, Gui, Philippe, Lea, Tasha, Wu, Wei, Urisman, Anatoly, Jones, Kirk, Sit, Rene, Kolli, Pallav K., Seeley, Eric, Gesthalter, Yaron, Le, Daniel D., Yamauchi, Kevin A., Naeger, David M., Bandyopadhyay, Sourav, Shah, Khyati, Cech, Lauren, Thomas, Nicholas J., Gupta, Anshal, Gonzalez, Mayra, Do, Hien, Tan, Lisa, Bacaltos, Bianca, Gomez-Sjoberg, Rafael, Gubens, Matthew, Jahan, Thierry, Kratz, Johannes R., Jablons, David, Neff, Norma, Doebele, Robert C., Weissman, Jonathan, Blakely, Collin M., Darmanis, Spyros, Bivona, Trever G.

Source: In Cell 3 September 2020 182(5):1232-1251

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study.

Authors: Blakely, Collin M., Urisman, Anatoly, Gubens, Matthew A., Mulvey, Claire K., Allen, Greg M., Shiboski, Stephen C., Rotow, Julia K., Chakrabarti, Turja, Kerr, D. Lucas, Aredo, Jacqueline V., Bacaltos, Bianca, Gee, Megan, Tan, Lisa, Jones, Kirk D., Devine, W. Patrick, Doebele, Robert C., Aisner, Dara L., Patil, Tejas, Schenk, Erin L., Bivona, Trever G.

Source: Journal of Clinical Oncology; 9/10/2024, Vol. 42 Issue 26, p3105-3114, 22p

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

Authors: Lara, Matthew S., Gubens, Matthew A., Bacaltos, Bianca, Daran, Lea, Lim, Steffany L., Li, Tianhong, Gandara, David R., Bivona, Trever G., Riess, Jonathan W., Blakely, Collin M.

Source: In JTO Clinical and Research Reports December 2022 3(12)

Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.

Authors: Blakely, Collin M., Gubens, Matthew A., Allen, Gregory M., Shah, Shrusti, Jereza, Matthew, Bacaltos, Bianca, Bandyopadhyay, Sourav

Source: Journal of clinical oncology. 39(15 suppl):9074-9074

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173219969.0x000001&indx=1&recIds=ETOCvdc_100173219969.0x000001

Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.

Authors: Aredo, Jacqueline V., Urisman, Anatoly, Gubens, Matthew A., Mulvey, Claire, Allen, Greg M., Rotow, Julia K., Kerr, Daniel Lucas, Chakrabarti, Turja, Bacaltos, Bianca, Gee, Megan, Jones, Kirk, Aisner, Dara L., Patil, Tejas, Schenk, Erin Lynn, Bivona, Trever G., Riess, Jonathan W., Coleman, Melissa, Kratz, Johannes Ruediger, Jablons, David, Blakely, Collin M.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8508-8508, 1p